Navigation Links
OncoGenex Reports Second Quarter 2009 Financial Results
Date:8/6/2009

be applied against taxes payable.

General and administrative expenses for the second quarter increased to $1.0 million from $0.6 million in 2008. For the six months ended June 30, 2009 general and administrative expenses increased to $1.8 million from $1.2 million in 2008. The increases in 2009 were primarily due to increased employee expenses and increased costs associated with operating as a public company.

The second quarter and six months ended June 30, 2008 also included $0.8 million and $1.6 million respectively in preferred share accretion, a non-cash item, which did not recur in the second quarter or six months ended June 30, 2009, as subsequent to the reverse takeover there are no preferred shares outstanding.

The Company had $5.7 million in cash, cash equivalents and short-term investments as of June 30, 2009, compared to $12.4 million in cash, cash equivalents and short-term investments as of December 31, 2008.

On July 24, 2009, subsequent to the end of the second quarter, the Company announced that it had completed a registered direct offering of 475,000 shares of its common stock to institutional investors at a price of $20.00 per share, for gross proceeds of $9.5 million. The $20.00 offering price represented a 3.5% discount to the closing price on July 17, 2009, the last trading day prior to announcement. After deducting the estimated offering expenses payable by the Company, the net proceeds are expected to be approximately $9.4 million. The Company had 6,027,631 shares outstanding as at August 5, 2009. The Company believes that its cash, cash equivalents and short-term investments will be sufficient to fund its currently planned operations at least through 2010, including:

    -  continuing survival follow-up for previously announced phase 2
       clinical trials of OGX-011;
    -  completion of its phase 1 clinical trial evaluating OGX-427 as a
       monotherapy in patients with solid tumors
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 30, 2014 Today the National ... of grants for the Brain Research through Advancing ... to develop and revolutionize new methods of understanding ... human brain. This first round of grants totaling ... was allocated to more than 100 investigators in ...
(Date:10/1/2014)... TeselaGen Biotechnology has received ... expand their bioCAD/CAM software suite, which uses synthetic ... Small Business Innovation Research Phase II grant will be ... license from the Lawrence Berkeley National Laboratory. j5 was ... LBNL laboratory that develops alternative fuel technologies for the ...
(Date:9/30/2014)... 30, 2014 Applying a well-known optical phenomenon ... Harvard University has demonstrated the ability to "paint" ... that holds promise for making future, flexible electronic ... sides of next-gen rocket ships and spacecraft with ... through oil in water, it becomes iridescent, revealing ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released the DSES-1000 long-travel ... for measuring displacement in rubber and other soft ... distance, the DSES-1000 can measure elongations up to ... mm. In addition, it achieves +/- 0.2 percent ... +/- 100 µm below 50-mm stroke. , The ...
Breaking Biology Technology:NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2
... the pro and cons of radio frequency identification technology ... at the second annual Wisconsin RFID Conference. Sponsored by ... at the steps for implementing RFID and predicted where ... about a product in an electronic tag. The tags ...
... MILWAUKEE - Metavante Corporation , a supplier of ... Corporation , has acquired two financial firms located in Virginia ... purchased GHR Systems , a provider of loan origination ... million and the deal is expected to close in the ...
... Wis. - It would be misleading to suggest that ... human embryos. They arent. In fact, no scientist in the ... ,It would also be disingenuous to suggest the process for ... at the outset -- from the process used in ...
Cached Biology Technology:Conference studies applications and lessons of RFID 2Conference studies applications and lessons of RFID 3The Attack of the Clones: No, its not a summer movie 2The Attack of the Clones: No, its not a summer movie 3
(Date:10/1/2014)... Reserve University researchers hope to take a healthy salad ... aggressive form of breast cancer in leafy greens. , ... the vaccine either by eating the salad or making ... assistant professor of biomedical engineering at Case Western Reserve ... The Susan G. Komen breast cancer organization is funding ...
(Date:10/1/2014)... 2014 Novel detection technology ... field  The life science field has ... the years. Some are shooting stars and others ... novel detection technology that has raised much enthusiasm ... technology is becoming commercially available. With their unique ...
(Date:9/30/2014)... visit the Mediterranean each year, but its deep-blue ... Earth. Almost 1,000 alien species, including fish, crustaceans, ... through human activities. In the open-access journal ... of researchers analyzed data from a new information ... how the introduction of alien species has changed ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3First-of-a-kind Solution for Utilizing Photon Upconversion 2Biodiversity in the Mediterranean is threatened by alien species 2
... bacteria that break down pollutants do their job and ... toxic wastes. , Bacteria called Dehalococcoides ethenogenes, discovered in ... professor of civil and environmental engineering, and isolated and ... now in wide use to detoxify such carcinogenic chemicals ...
... announced the publication in the June 23 issue of the ... gene therapy trial for Parkinson’s disease and the first report ... for any adult neurodegenerative disease. , The open label ... disease demonstrated both a lack of adverse events related to ...
... in the United States and other northern mid- ... in offsetting global warming than previously thought, according ... The study, which sheds light on the so-called ... are removing an unexpectedly high proportion of carbon ...
Cached Biology News:Helping chlorine-eating bacteria clean up toxic waste 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 3Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 4Scientists close in on missing carbon sink 2Scientists close in on missing carbon sink 3
... plus assay system offers the ... Designed for batch-processing systems, Long ... density microplates such as 384-well ... Convenient storage conditions ( 2 ...
Sf21 cells derived from Spodoptera frugiperda ovarian cells are recommended for high-level production of recombinant proteins. Higher expression levels of some proteins are seen due to the larger ce...
... steadylite plus assay system offers ... sensitivity, Designed for batch-processing systems, ... higher density microplates such as ... free, Convenient storage conditions ( ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
Biology Products: